Aptus Pharma IPO Funds Fully Accounted For: CARE Ratings Confirms Zero Deviation

Aptus Pharma Ltd has confirmed that its entire ₹13.02 crore in IPO proceeds have been fully utilized as disclosed. The largest allocation was ₹8.00 crore for working capital needs.

Reader Takeaway: IPO fund compliance assured; maintaining growth remains key.

CARE Ratings Verifies IPO Fund Usage

Aptus Pharma Limited has submitted its Monitoring Agency Report for the period ending March 31, 2026, to the BSE. Prepared by CARE Ratings Limited, the report confirms the company fully utilized its ₹13.02 crore Initial Public Offer (IPO) proceeds according to its Offer Document.

This means there has been no deviation or variation in how the funds were deployed. Specific allocations were ₹1.63 crore for Capital Expenditure (Office Premises), ₹8.00 crore for Working Capital, ₹1.91 crore for General Corporate Purposes, and ₹1.48 crore for Offer Expenses.

The report confirms the company's commitment to transparency and regulatory disclosures. Fund utilization was verified through Chartered Accountant certificates, management confirmations, bank statements, and sample invoices.

Why This Report Matters to Investors

This report offers investors crucial assurance about the responsible deployment of capital raised from the public. It signals strong corporate governance and a commitment to fulfilling IPO promises, building trust and potentially boosting investor sentiment.

Aptus Pharma's Business Model and IPO Background

Aptus Pharma Limited, a pharmaceutical marketing and distribution firm using an asset-light model, raised ₹13.02 crore through its SME IPO. The issue ran from September 23 to September 25, 2025, with shares listing on the BSE SME platform on September 30, 2025, at ₹70 per share. The company partners with WHO-GMP-certified facilities for manufacturing, focusing its capital on marketing and brand development.

Key Changes and Investor Confidence

• Shareholders gain confidence in the company's financial discipline and adherence to IPO commitments.
• The company strengthens its reputation for transparency with regulatory bodies and the investing community.
• The confirmation of fund utilization clears a potential point of scrutiny, allowing focus to shift to operational performance.
• It validates the company's strategy of using IPO funds for core operational needs like working capital and general corporate purposes.

Potential Risks for Aptus Pharma

While the IPO fund utilization report is clean, Aptus Pharma faces potential risks:

• Increased debtor days (from 99.8 to 147) and working capital days (from 73.4 to 117) could strain liquidity if not managed effectively.
• A significant portion of revenue is derived from a few key customers, posing a concentration risk.

Aptus Pharma's Market Position and Strategy

Aptus Pharma operates in the competitive pharmaceutical sector, distinct from larger players like Sun Pharma, Divi's Laboratories, Torrent Pharma, and Cipla. Unlike peers with extensive manufacturing infrastructure, Aptus Pharma uses an asset-light model, partnering with contract manufacturers. This strategy conserves capital and focuses resources on marketing and distribution, a key growth differentiator.

Key Financial Metrics and Performance

• The IPO raised ₹13.02 crore between September 23-25, 2025.
• Funds utilized for working capital amounted to ₹8.00 crore for the half year and year ended March 31, 2026.
• The company's share price was ₹438 as of May 5, 2026, significantly higher than its IPO issue price of ₹70.

What Investors Should Track Next

• Continued adherence to financial disclosures and regulatory compliance.
• The company's performance in managing its increased working capital and debtor days.
• Growth trajectory and market penetration as the company expands its product portfolio and distribution network.
• Impact of the recently approved 3:2 bonus share issue on its capital structure and shareholder value.
• Future quarterly financial results for operational performance updates.